PepGen (NASDAQ:PEPG) Releases Earnings Results, Misses Estimates By $0.01 EPS

PepGen (NASDAQ:PEPG) issued its earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01), FiscalAI reports.

Here are the key takeaways from PepGen’s conference call:

• PepGen reported a 46.5% mean improvement in splicing after four doses of PGN-EDODM1 at 10 mg/kg, with four of six treated participants exceeding 50% improvement. The company said this was the highest mean splicing correction reported to date in a multiple-dose DM1 study.
• The company also reported improvements across several functional measures: myotonia improved by 4.3 seconds at week 13, while hand grip strength improved 16% at week 16, alongside favorable changes in timed mobility tests. These results come from a small cohort and are early; patient-reported outcomes did not yet show a clear signal.
• Management described the treatment as generally well tolerated, with no serious adverse events, dose-limiting toxicities, or discontinuations. Four mild kidney-related events were reported; albuminuria was transient, and the company said it saw no meaningful changes in eGFR or serum creatinine.
• The U.S. multiple-ascending-dose study remains under a partial FDA clinical hold related to questions about prior mouse toxicology findings. PepGen said it is conducting additional mouse studies to address the agency’s concerns, although the hold has not stopped the ongoing study in other countries.
• PepGen expects to report longer-term safety data at 10 mg/kg and additional data from the open-label extension in January 2027, with results from the 12.5 mg/kg cohort expected in the first half of 2027. The company said these data will inform dose selection and discussions with regulators about a pivotal trial.

PepGen Stock Up 127.2%

NASDAQ:PEPG traded up $3.04 during trading hours on Tuesday, hitting $5.43. 73,945,673 shares of the company traded hands, compared to its average volume of 1,354,017. The firm’s 50-day simple moving average is $2.66 and its 200-day simple moving average is $2.98. PepGen has a one year low of $1.31 and a one year high of $7.80. The company has a market cap of $376.15 million, a PE ratio of -4.16 and a beta of 2.02.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PEPG. Wall Street Zen raised shares of PepGen from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings upgraded shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Finally, HC Wainwright restated a “buy” rating on shares of PepGen in a report on Wednesday, September 9th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.40.

PepGen Company Profile

PepGen Inc is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.